With a market capitalization (market cap) of $1.39B — a measure of how much the company is worth — Inhibrx Biosciences Inc. is the 2358th most valuable company in Healthcare as of August 19, 2026. Shares trade at $94.62, up +2.84% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Visit websiteAs of August 19, 2026, Inhibrx Biosciences Inc. (INBX) is worth $1.39B — this is its market capitalization, the total value of all its outstanding shares.
Inhibrx Biosciences Inc.’s market cap is $1.39B, which ranks it #2358 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Inhibrx Biosciences Inc. (INBX) shares trade at $94.62, up 2.84% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025